2015 Autumn Conference
Includes Joint Day with ECNP
27 – 29 August, 2015 // Amsterdam Marriott Hotel // Amsterdam, NL
Poster Awardees: |
||
|
Bipolar Depression: Acute Stable Response to Medication as a Predictor of Long-term Treatment Response (Iosifescu) Quantifying Myelin Kinetics in Healthy Subjects Using Deuterium Labeling (Kanhai) |
||
|
All Poster PDFs and Abstracts are available at the end of the second day. |
||
27 August 2015 |
||
| Welcome Reception | ||
28 August 2015 (Includes Joint Sessions with ECNP) |
||
| Welcome from the Presidents | R Keefe for S Romano slidesG Goodwin slides video |
|
| Session 1: Challenges in Utilizing Outcome Measures Across Regions and Cultures | Chairs: ISCTM Chair, R Keefe ECNP Chair, S Leucht |
|
| Cultural issues in psychiatric outcomes for global trials | S Leucht slides video |
|
| Challenges of multinational European schizophrenia studies | W Fleischhacker slides video |
|
| Multi-national clinical trial outcomes in international studies of bipolar disorder | E Vieta slides video |
|
| Workgroup on International clinical trials update: Translation and adaptation of clinician rated outcomes | A Kalali slides video |
|
| Regulatory comments | V Mantua** K Broich* video |
|
| Panel and Audience Discussion | All Speakers video |
|
| Session 2: Cognitive Impairment in Major Depressive Disorder as a Target for Drug Development | ECNP Chair, C Harmer ISCTM Chair, T Laughren |
|
| Introduction | C Harmer* video |
|
| Overview of CI in MDD as an unmet need | M Fava slides video |
|
| Objective measures of cognitive impairment in depression | G Goodwin slides video |
|
| Targeting cognitive impairment in major depressive disorder- industry perspective | C Kurre Olsen slides video |
|
| Regulatory challenges in targeting cognitive impairment in depression | K Broich slides video T Laughren slides video |
|
| Panel and Audience Discussion | All Speakers video |
|
| Session 3: An Update on Critical Issues for Alzheimer’s Disease | ISCTM Chair, R Anand ECNP Chair, G Knudsen |
|
| Welcome and introduction | G Knudsen slides video |
|
| Critical issues in Alzheimer’s Disease and outlook for the future | R Anand slides** |
|
| Amyloid pathways and disease-modifying treatments for AD: What changes are necessary in new trials? | J Hardy slides video |
|
| 50 ways to improve your trial in AD | P Scheltens slides |
|
| Evidence from amyloid – modifying treatments: Are we learning anything about the treatment of AD? | R Doody** | |
| How can the new diagnostic criteria improve patient selection for DM therapy trials | B Dubois slides |
|
| Is there a need for new symptomatic therapies for Alzheimer’s Disease and what have we learned from past trials of symptomatic therapies? | G Grossberg slides |
|
| Regulatory efforts to streamline the pathway for developing novel treatments for AD | K Broich slides |
|
| Roundtable Discussion | R Anand G Knudsen |
|
| Adjourn Joint Meeting | R Keefe for S Romano |
|
| ISCTM Poster Session / Reception | Poster Abstracts and PDFs | |
29 August 2015 |
||
| Session 4: Continued Challenges with Placebo Response in CNS Trials: What Has Changed and What Have We Learned in Mood Disorders, Schizophrenia and Pain | Chairs: R Keefe for S Romano G Groeneveld |
|
| Introduction | R Keefe for S Romano* |
|
| The neurobiology of placebo and its implications for clinical trials | F Benedetti** | |
| Placebo response in MDD/Bipolar studies | E Vieta slides |
|
| Placebo effect in schizophrenia studies | M Davidson slides |
|
| The placebo conundrum | A Dahan** | |
| Dogma, myths, silos, and assumptions: Can we do better? | A Kalali** | |
| Panel Discussion | All Speakers |
|
| Meeting Adjourns | R Keefe for S Romano | |
| * No slides presented ** Slides not currently released
|
||